Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Home
Profiles
Research units
Research output
Search by expertise, name or affiliation
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial
FORCIDP Trial Investigators
School of Medicine
Research output
:
Contribution to journal
›
Article
›
peer-review
14
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine & Life Sciences
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
100%
Fingolimod Hydrochloride
98%
Randomized Controlled Trials
47%
Intravenous Immunoglobulins
47%
Placebos
39%
Adrenal Cortex Hormones
28%
Random Allocation
20%
Survival
11%
Experimental Autoimmune Neuritis
11%
Clinical Trials Data Monitoring Committees
10%
Medical Futility
9%
Relapsing-Remitting Multiple Sclerosis
8%
Therapeutics
8%
Israel
7%
Neurology
7%
Double-Blind Method
6%
Duration of Therapy
6%
Canada
6%
Japan
5%
Extremities
5%
Hypertension
4%
Pain
4%
Recurrence
4%